Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma (Inova-CCP)
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2)
Sponsor: Inova Health Care Services
Terminated
FDA gave emergency use approval to COVID-19 convalescent plasma on 08/24/2020
Other terminated trials from Inova Health Care Services
- Gestational Diabetes Mellitus, Class A2 · Phase NA · May 2024
- Peripheral Arterial Disease · Oct 2019
- Diabetes Mellitus, Type 2 · Phase PHASE4 · Oct 2019
- Non-ST Elevation Myocardial Infarction (NSTEMI) · Jun 2019
- Chronic Obstructive Pulmonary Disease (COPD) · Phase PHASE2 · Jan 2019
More terminations from Inova Health Care Services
This PHASE2/PHASE3 trial investigates Covid-19 and is currently terminated or withdrawn. Inova Health Care Services leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Feb 2022 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
Status: Recruiting → Terminated
-
Jan 2021 — Feb 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Inova Health Care Services
For direct contact, visit the study record on ClinicalTrials.gov .